Medicus Pharma (MDCXW) Equity Average (2024 - 2025)
Medicus Pharma (MDCXW) reported Equity Average of -$488840.0 for Q4 2025, down 112.33% on a YoY basis from $4.0 million in Q4 2024, and down 141.81% quarter-over-quarter from $1.2 million in Q3 2025.
Medicus Pharma (MDCXW) Equity Average (2024 - 2025) Analysis & Trends
Medicus Pharma has reported Equity Average for 2 years, with the latest figure at -$488840.0 in Q4 2025.
- For the quarter ending Q4 2025, Equity Average fell 112.33% year-over-year to -$488840.0; the trailing twelve-month figure through Dec 2025 stood at -$488840.0 (down 112.33% YoY), and the FY2025 full-year result was $1.5 million, down 27.77% from the prior year.
- Equity Average for Q4 2025 stood at -$488840.0, down from $1.2 million in the prior quarter.
- The five-year high for Equity Average was $5.9 million in Q3 2024, with the low at -$488840.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 28.87 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 81.37 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -4.96 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 49.27 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 8.92 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 23.11 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 88.29 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 19.27 Bn |
| 10 | Medicus Pharma | - | - | - | -488,840.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -488,840.00 |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 2.64 Mn |
| Dec 31, 2024 | 3.96 Mn |
| Sep 30, 2024 | 5.93 Mn |
| Jun 30, 2024 | 3.26 Mn |
| Mar 31, 2024 | 275,745.50 |